1 / 35

Systolic Blood Pressure Intervention Trial Goals and Rationale

Systolic Blood Pressure Intervention Trial Goals and Rationale. American Society of Hypertension May 20, 2012 Karen C. Johnson, MD, MPH University of Tennessee Health Science Center. American Society of Hypertension, Inc. (ASH). Disclosure of Relationships.

derry
Download Presentation

Systolic Blood Pressure Intervention Trial Goals and Rationale

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Systolic Blood Pressure Intervention Trial Goals and Rationale American Society of Hypertension May 20, 2012 Karen C. Johnson, MD, MPH University of Tennessee Health Science Center

  2. American Society of Hypertension, Inc. (ASH) Disclosure of Relationships Over the past 12 months Karen C. Johnson MD, MPH has received grant funds from the National Heart Lung and Blood Institute (NHLBI) and the National Institute of Diabetes, Digestive, and Kidney Disease (NIDDK) of National Institutes of Health (NIH)

  3. Systolic Blood Pressure Intervention Trial SPRINT is a randomized controlled clinical trial examining the effect of a high blood pressure treatment strategy aimed at reducing systolic blood pressure (SBP) to a lower goal than is currently recommended.

  4. SPRINT Important Goals SPRINT will test whether a treatment strategy aimed at reducing systolic blood pressure to: • lower goal (SBP < 120 mm Hg) compared with • currently recommended (SBP < 140 mm Hg) will reduce the occurrence of cardiovascular disease (CVD). N = 9250

  5. SPRINT Primary Outcome • Composite of • MI • Stroke • Heart failure • Acute coronary syndrome • Cardiovascular death • The primary hypothesis is that CVD event rates will be lower in the intensive intervention arm.

  6. SPRINT Other Outcomes Renal outcomes For Chronic Kidney Disease (CKD), composite of: ESRD or 50% decline in eGFR For non-CKD, progression to CKD: ESRD or 30% decrease in eGFR to a value of < 60 mL/min/1.73m2

  7. SPRINT Other Outcomes SPRINT MIND will test whether the lower SBP goal influences the occurrence of dementia, change in cognition, and change in brain structure (on MRI).

  8. Major Inclusion Criteria • At least 50 years old • Systolic blood pressure • SBP: 130 – 180 mm Hg on 0 or 1 medication • SBP: 130 – 170 mm Hg on up to 2 medications • SBP: 130 – 160 mm Hg on up to 3 medications • SBP: 130 – 150 mm Hg on up to 4 medications • Risk (one or more of the following) • Presence of clinical or subclinical CVD (not stroke) • Chronic Kidney Disease (CKD), defined as eGFR 20 – 59 ml/min/1.73m2 • Framingham Risk Score for 10-year CVD risk ≥ 15% • Not needed if eligible based on preexisting CVD or CKD • Age ≥ 75 years

  9. Major Exclusion Criteria Stroke Diabetes Congestive heart failure (symptoms or EF < 35%) Proteinuria >1g/d CKD with eGFR < 20 mL/min/1.73m2 (MDRD) Adherence flags

  10. SPRINT Intensive Intervention Blood pressure medications are added and/or titrated at each study visit to achieve SBP <120 mm Hg Intervention goal is to create a minimum mean difference between randomized groupsof at least 10 mm Hg

  11. SPRINT Standard Intervention • Intensify therapy if: • SBP ≥160 mm Hg @ 1 visit • ≥140 mm Hg @ 2 consecutive visits • Down-titration if: • SBP <130 mm Hg @ 1 visit • <135 mm Hg @ 2 consecutive visits

  12. Medication Classes Provided by SPRINT • Angiotensin converting enzyme (ACE)-inhibitors • Angiotensin receptor blockers (ARBs) • Direct vasodilators • Thiazide-type diuretics • Loop diuretics • Potassium-sparing diuretics • Beta-blockers • Sustained-release calcium channel blockers (CCBs) • Alpha1-receptor blockers • Sympatholytics

  13. Why is NIH Conducting SPRINT? • High blood pressure is one of the most common conditions among middle-aged and older adults, and is a leading risk factor for stroke, heart disease, chronic kidney disease, and other conditions. • Previous trials demonstrate effectiveness of treating SBP to about 140 mm Hg. • Observational studies suggest benefits of SBP lowering may extend to levels below 120 mm Hg. • SPRINT will provide critical evidence regarding feasibility and benefits and potential risks of more intensive BP control.

  14. Why is NIH Conducting SPRINT? • High blood pressure is one of the most common conditions among middle-aged and older adults, and is a leading risk factor for stroke, heart disease, chronic kidney disease, and other conditions. • Previous trials demonstrate effectiveness of treating SBP to about 140 mm Hg. • Observational studies suggest benefits of SBP lowering may extend to levels below 120 mm Hg. • SPRINT will provide critical evidence regarding feasibility and benefits and potential risks of more intensive BP control.

  15. Why is NIH Conducting SPRINT? • High blood pressure is one of the most common conditions among middle-aged and older adults, and is a leading risk factor for stroke, heart disease, chronic kidney disease, and other conditions. • Previous trials demonstrate effectiveness of treating SBP to about 140 mm Hg but treating to this goal is challenging • Observational studies suggest benefits of SBP lowering may extend to levels below 120 mm Hg. • SPRINT will provide critical evidence regarding feasibility and benefits and potential risks of more intensive BP control.

  16. BP Lowering Treatment is Effective but Challenging Average Percent Reduction in previous trials targeting higher SBP goals • Stroke incidence: ~35-40% • Myocardial Infarction: ~20-25% • Heart Failure: ~50% Benefits relate to extent of SBP lowering Multiple medications often needed for control but significant side-effects may occur Lancet. 2000;356:1955-64.

  17. Major Cardiovascular Events Relative risk of major CVD Systolic blood pressure difference between randomised groups (mmHg) Lancet 2003; 362: 1527–35.

  18. Combination Therapy Is Often Needed to Achieve Target SBP Goals Trial (SBP Achieved) UKPDS (144 mm Hg) RENAAL (141 mm Hg) ALLHAT (138 mm Hg) IDNT (138 mm Hg) HOT (138 mm Hg) INVEST (133 mm Hg) ABCD (132 mm Hg) MDRD (132 mm Hg) AASK (128 mm Hg) 1 2 3 4 BP Agents (number) Am J Kidney Dis. 2000;36:646-661.

  19. Why is NIH Conducting SPRINT? • High blood pressure is one of the most common conditions among middle-aged and older adults, and is a leading risk factor for stroke, heart disease, chronic kidney disease, and other conditions. • Previous trials demonstrate effectiveness of treating SBP to about 140 mm Hg. • Observational studies suggest benefits of SBP lowering may extend to levels below 120 mm Hg. • SPRINT will provide critical evidence regarding feasibility and benefits and potential risks of more intensive BP control.

  20. Ischemic Heart Disease Mortality Rate in Each Decade of Age SBP DBP Age at risk: 256 256 80-89 y 128 128 70-79 y 64 64 60-69 y 32 32 IHDmortality (absolute risk and 95% CI) 50-59 y 16 16 40-49 y 8 8 4 4 2 2 1 1 120 140 160 180 70 80 90 100 110 Usual SBP (mm Hg) Usual DBP (mm Hg) Lancet. 2002;360:1903-1913.

  21. Meta-Analysis: Treating to BP Goals Lower Than 140/90 mmHg Does Not Reduce Mortality or Morbidity Arguedas JA, et al. Cochrane Database Syst. Rev. 2009:CD004349.

  22. POTENTIAL COSTS / RISKS OF LOWER THAN INDICATED BP TARGETS • Increased cost of potentially unnecessary medications • Increased risk of medication side effects • Increased clinic visits if BP not at lower goal • Increased monitoring required • More complicated regimen that may jeopardize adherence to evidence-based treatment of other risk factors • Potential increased risk of lower BP goals

  23. Why is NIH Conducting SPRINT? • High blood pressure is one of the most common conditions among middle-aged and older adults, and is a leading risk factor for stroke, heart disease, chronic kidney disease, and other conditions. • Previous trials demonstrate effectiveness of treating SBP to about 140 mm Hg. • Observational studies suggest benefits of SBP lowering may extend to levels below 120 mm Hg. • SPRINT will provide critical evidence regarding feasibility of lowering blood pressure to lower goals and benefits and potential risks of more intensive BP control.

  24. Clinical Trial Evidence of Lower SBP Goals is Unclear • ACCORD • BP question: Does a strategy targeting systolic blood pressure (SBP) <120 mm Hg reduce CVD events compared to a strategy targeting SBP <140 mm Hg in 4,700 participants with type 2 diabetes at high risk for CVD events?

  25. ACCORD Results are Mixed

  26. ACCORD Adverse Events N Engl J Med. 2010;362:1575-85

  27. Will the SPRINT Intervention produce an adequate difference in SBP?

  28. ACCORD Systolic Pressures Mean # Meds Intensive: 3.2 3.4 3.5 3.4 Standard: 1.9 2.1 2.2 2.3 Average after 1st year: 133.5 Standard vs. 119.3 Intensive, Delta = 14.2 N Engl J Med. 2010;362:1575-85

  29. Equipoise • The SPRINT hypothesis has never been tested in a randomized clinical trial setting in participants without diabetes or stroke • Epidemiologic data is suggestive of benefit • The ACCORD results, though negative overall, did not rule out substantial benefit, however there may be increased risk of certain adverse events with lower blood pressures

  30. Summary • High blood pressure is a leading cause of death and disability in the US and world-wide. • Current treatment approaches are effective, but challenging, and may leave residual risk due to hypertension at levels of 140 mm Hg. • More intensive control of SBP might prevent strokes, CVD, dementia, and progression of chronic kidney disease. • SPRINT will provide critical evidence on these important questions.

  31. For more information Visit www.SPRINTTrial.org

  32. SPRINT Symposia Speakers • SPRINT Design – Walter Ambrosius, PhD • SPRINT and Chronic Kidney Disease – Alfred Cheung, MD • SPRINT Mind – Jeff Williamson, MD

  33. Take Home Message Evidence from previous studies suggests that the benefits to treating to a lower systolic blood pressure goal outweigh the risk but this has not been tested in a clinical trial setting in persons at high risk for CVD. SPRINT is designed to test this lower systolic blood pressure goal of < 120 mm Hg.

  34. American Society of Hypertension, Inc. (ASH) Disclosure of Relationships Over the past 12 months Karen C. Johnson MD, MPH has received grant funds from the National Heart Lung and Blood Institute (NHLBI) and the National Institute of Diabetes, Digestive, and Kidney Disease (NIDDK) of National Institutes of Health (NIH)

  35. Questions

More Related